Nimotuzumab Plus Chemoradiation for Older Adults with Esophageal Cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests adding nimotuzumab, a targeted therapy, to standard chemoradiation for elderly patients with esophageal squamous cell cancer. It aims to see if the combination improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 70 years or older
- You have esophageal squamous cell cancer that is stage II to IVB (with limited spread to lymph nodes only)
- You are able to undergo chemotherapy and radiation at the same time
- Your overall health is good (ECOG score 0 or 1, meaning you are fully active or active but not bedridden)
- You have not had treatment with EGFR antibodies or EGFR-TKIs in the past 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests whether adding immunotherapy to standard chemoradiation can help people with unresectable locally advanced esophageal cancer. It aims to improve outcomes for those who cannot have surgery.
This trial tests a new combination of two chemotherapy drugs (liposomal irinotecan and cisplatin) given together with radiation therapy for locally advanced esophageal cancer. It aims to see if this treatment is safe and effective, potentially offering a new option for patients who cannot have surgery.
This trial compares the usual treatment (chemotherapy plus radiation before surgery) with a combination that also includes an immunotherapy drug called sintilimab. The goal is to see if adding immunotherapy helps shrink the tumor and improve outcomes for patients with esophageal cancer that can be removed by surgery.
This trial tests a new immunotherapy drug called serplulimab combined with standard chemotherapy and radiation for older adults with locally advanced esophageal cancer. It aims to see if this combination can help shrink tumors and improve outcomes without prior cancer treatment.
This trial tests adding the targeted drug nimotuzumab to standard chemotherapy and radiation for people with esophageal cancer that cannot be removed by surgery. It may help shrink the tumor or stop it from growing further.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.